Who are Haloart's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Durezol, Arnuity Ellipta, Omnaris, Omnaris, Mifeprex, Lotemax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/halopredone-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Haloart — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haloart (HALOPREDONE ACETATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: halopredone. Area: Immunology.

phase 2 halopredone Glucocorticoid receptor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Haloart (HALOPREDONE ACETATE). Haloart works by binding to the glucocorticoid receptor, a protein that regulates the body's response to stress and inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Haloart TARGET	HALOPREDONE ACETATE		phase 2	halopredone	Glucocorticoid receptor
Durezol	DIFLUPREDNATE	Novartis	marketed	difluprednate	Glucocorticoid receptor	2008-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	marketed	Corticosteroid	Glucocorticoid receptor	2007-01-01
Omnaris	CICLESONIDE	Covis	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Omnaris	Alvesco	Takeda Gmbh	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Mifeprex	MIFEPRISTONE	Corcept Therap	marketed	Progestin Antagonist [EPC]	Glucocorticoid receptor	2000-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	marketed	Corticosteroid	Glucocorticoid receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-02-01 — Omnaris · 8371292 · US
2033-05-03 — Lotemax · 9056057 · Formulation · US
2033-05-03 — Lotemax · 9532955 · Method of Use · US
2033-05-03 — Lotemax · 10058511 · Formulation · US
2033-05-03 — Lotemax · 11219596 · Method of Use · US
2033-05-03 — Lotemax · 11219597 · Method of Use · US
2033-05-03 — Lotemax · 11596599 · Method of Use · US
2033-05-03 — Lotemax · 10857096 · Method of Use · US
2033-05-03 — Lotemax · 10864219 · Method of Use · US
2033-05-03 — Lotemax · 10945948 · Method of Use · US
2033-05-03 — Lotemax · 10940108 · Method of Use · US
2033-05-03 — Lotemax · 9737491 · Method of Use · US
2033-05-03 — Lotemax · 9827191 · Formulation · US
2033-05-03 — Lotemax · 11872318 · Formulation · US
2033-05-03 — Lotemax · 9393213 · Formulation · US
2033-05-03 — Lotemax · 10646436 · Formulation · US
2033-05-03 — Lotemax · 10993908 · Method of Use · US
2033-05-03 — Lotemax · 12115246 · Formulation · US
2033-05-03 — Lotemax · 10688045 · Formulation · US
2033-05-03 — Lotemax · 11642317 · Formulation · US
2033-05-03 — Lotemax · 10646437 · Formulation · US
2036-01-26 — Lotemax · 11534395 · Formulation · US
2036-12-23 — Lotemax · 10596107 · Formulation · US

Sponsor landscape (halopredone class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Haloart — Competitive Intelligence Brief. https://druglandscape.com/ci/halopredone-acetate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing